The Symplicity HTN-1 study demonstrated that renal denervation by radiofrequency ablation significantly reduced blood pressure (BP) in patients with drug-resistant hypertension at 1 and 12 months. A new analysis in the Lancet shows that this benefit was sustained at 3 years after therapy. Among 88 patients for whom data were complete at 36 months, systolic BP was reduced by 32.0 mmHg (95% CI −35.7 mmHg to −28.2 mmHg), and diastolic BP by 14.4 mmHg (95% CI −16.9 mmHg to −11.9 mmHg). The investigators conclude that “renal denervation seems to offer a novel and complementary approach for patients in whom pharmacological options seem exhausted. Adequately powered clinical trials with long-term follow-up are warranted to confirm these results”.
References
Krum, H. et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 10.1016/S0140-6736(13)62192-3
Rights and permissions
About this article
Cite this article
Benefits of renal denervation persist at 3 years—data from Symplicity HTN-1. Nat Rev Cardiol 11, 2 (2014). https://doi.org/10.1038/nrcardio.2013.178
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.178